Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin-In Reply

Tracey G Simon^{1

2

3}, Andrew T Chan^{1

2

3

4

5

6}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.
³ Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston.
⁴ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston Massachusetts.
⁵ Broad Institute, Boston Massachusetts.
⁶ Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston Massachusetts.

Comment

Tracey G Simon et al. JAMA Oncol. 2019.

. 2019 Jun 1;5(6):911-912.

doi: 10.1001/jamaoncol.2019.0630.

Tracey G Simon^{1

2

3}, Andrew T Chan^{1

2

3

4

5

6}

¹ Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.
³ Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston.
⁴ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston Massachusetts.
⁵ Broad Institute, Boston Massachusetts.
⁶ Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston Massachusetts.

No abstract available

Comment on

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.
Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Simon TG, et al. JAMA Oncol. 2018 Dec 1;4(12):1683-1690. doi: 10.1001/jamaoncol.2018.4154. JAMA Oncol. 2018. PMID: 30286235 Free PMC article.
Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin.
Chien N, Yeo YH, Nguyen MH. Chien N, et al. JAMA Oncol. 2019 Jun 1;5(6):911. doi: 10.1001/jamaoncol.2019.0614. JAMA Oncol. 2019. PMID: 31046061 No abstract available.